Lilly (Eli) vs Merck &
Lilly (Eli) and Merck & are similar in size: $65.18bn and $65.01bn of revenue in their latest fiscal years. Lilly (Eli) grew faster (44.7% against 1.3%). Lilly (Eli) kept more of each dollar of sales as profit: a net margin of 31.7% against 28.1%. Merck & carries less debt relative to equity (93.8% against 160.2%).
| Latest fiscal year | Lilly (Eli)LLY, 2025 | Merck &MRK, 2025 |
|---|---|---|
| Revenue | $65.18bn | $65.01bn |
| Revenue growth | 44.7% | 1.3% |
| Net income | $20.64bn | $18.25bn |
| Operating margin | — | — |
| Net margin | 31.7% | 28.1% |
| Return on equity | 101.2% | 36.9% |
| Free cash flow | $8.97bn | $12.36bn |
| Cash | $7.27bn | $14.56bn |
| Total debt | $42.50bn | $49.34bn |
| Debt to equity | 160.2% | 93.8% |
| Dividend per share | $6.23 | $3.28 |
| Dividend yield | 0.5% | 2.3% |
| Share buybacks | $4.11bn | $5.08bn |
| Employees | 50,000 | — |
| Market value | $1.26tn | $354.85bn |
| Price vs our value range | Above our value range | Above our value range |
| Moat score | 78 (Strong) | 79 (Strong) |
| Insider trades, 12 months | 0 buys, 240 sales | 0 buys, 35 sales |